These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 19179043)

  • 1. Indirect comparison: relative risk fallacies and odds solution.
    Eckermann S; Coory M; Willan AR
    J Clin Epidemiol; 2009 Oct; 62(10):1031-6. PubMed ID: 19179043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent validity to those carried out under double-blind conditions?
    O'Neil WM; Welner SA; Lip GY
    Thromb Haemost; 2013 Mar; 109(3):497-503. PubMed ID: 23348922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network analysis of randomized controlled trials in multiple sclerosis.
    Zintzaras E; Doxani C; Mprotsis T; Schmid CH; Hadjigeorgiou GM
    Clin Ther; 2012 Apr; 34(4):857-869.e9. PubMed ID: 22444787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.
    Chaudhari D; Bhuriya R; Arora R
    Am J Ther; 2011 Jan; 18(1):e1-e11. PubMed ID: 20460986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269].
    Mant JW; Richards SH; Hobbs FD; Fitzmaurice D; Lip GY; Murray E; Banting M; Fletcher K; Rahman J; Allan T; Raftery J; Bryan S;
    BMC Cardiovasc Disord; 2003 Aug; 3():9. PubMed ID: 12939169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab versus interferon beta-1a: implications for pathology and trial design.
    McFarland HF
    Lancet Neurol; 2009 Jan; 8(1):26-8. PubMed ID: 19081510
    [No Abstract]   [Full Text] [Related]  

  • 14. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing stroke in patients with atrial fibrillation.
    Edds W; Newton W
    J Fam Pract; 2000 Jan; 49(1):8-9. PubMed ID: 10678330
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspirin versus warfarin in atrial fibrillation: decision analysis may help patients' choice.
    Romero-Ortuno R; O'Shea D
    Age Ageing; 2012 Mar; 41(2):250-4. PubMed ID: 22156597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet versus anticoagulant therapies in advanced age: an unfinished task.
    García-Honrubia A; Roldán V; Climent V; Sogorb F; Marín F
    Int J Cardiol; 2006 Jun; 110(2):271-2. PubMed ID: 16343666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
    Stöllberger C; Finsterer J
    Thromb Haemost; 2013 Sep; 110(3):496-500. PubMed ID: 23803875
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.